Skip to main content

Day: May 13, 2020

Orchid Island Capital Announces May 2020 Monthly Dividend and April 30, 2020 RMBS Portfolio Characteristics

May 2020 Monthly Dividend of $0.055 Per Share of Common StockRMBS Portfolio Characteristics as of April 30, 2020Next Dividend Announcement Expected June 16, 2020VERO BEACH, Fla., May 13, 2020 (GLOBE NEWSWIRE) — Orchid Island Capital, Inc. (the “Company”) (NYSE:ORC) announced today that the Board of Directors (the “Board”) declared a monthly cash dividend for the month of May 2020. The dividend of $0.055 per share will be paid June 26, 2020, to holders of record of the Company’s common stock on May 29, 2020, with an ex-dividend date of May 28, 2020. The Company plans on announcing its next common stock dividend after the Board’s meeting on June 16, 2020.The Company intends to make regular monthly cash distributions to its holders of common stock. In order to qualify as a real estate investment trust (“REIT”), the Company must distribute...

Continue reading

Ascendant Resources Reports First Quarter 2020 Results

●  Results include the El Mochito Mine which was sold subsequent to quarter end and is shown as a discontinued operationQ1 2020 Highlights:Contained metal production of 28.8 million ZnEq1lbs, up 23% vs Q1/19ZnEq grade of 7.8%, a 16% improvement over Q1/19Net Revenue from discontinued operations of $13.78 million, down 23% from Q1/19 and down 31% from Q4/19, due to a negative provisional price adjustment of $12.35 millionSignificant improvement in AISC of $1.03/lb ZnEq versus $1.30/lb ZnEq in Q1/19Adjusted EBITDA loss of $9.30 million versus $1.45 million gain in Q1/19Net Loss of $11.14 million and loss per share of $0.14Sale of El Mochito mine subsequent to the end of Q1/20 announced April 17, 2020(All dollar amounts are in U.S. dollars (“$”) unless otherwise specified)TORONTO, May 13, 2020 (GLOBE NEWSWIRE) — Ascendant Resources...

Continue reading

G1 Therapeutics to Present Data Showing Myelopreservation Benefits of Trilaciclib in Patients with Small Cell Lung Cancer at the ASCO20 Virtual Scientific Program

– Trilaciclib significantly reduced myelosuppression and need for related supportive care interventions for patients with small cell lung cancer (SCLC) receiving chemotherapy– New Drug Application (NDA) submission for trilaciclib in SCLC on track for completion in 2Q20RESEARCH TRIANGLE PARK, N.C., May 13, 2020 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that data across three randomized, double-blind, placebo-controlled Phase 2 trials of the investigational therapy trilaciclib in small cell lung cancer (SCLC) will be presented on May 29 at the ASCO20 Virtual Scientific Program of the American Society of Clinical Oncology (ASCO). In these trials, trilaciclib was administered prior to chemotherapy treatment and significantly reduced rates of myelosuppression...

Continue reading

Parkland Fuel Corporation Announces May 2020 Dividend

CALGARY, Alberta, May 13, 2020 (GLOBE NEWSWIRE) — Parkland Fuel Corporation (“Parkland”) (TSX:PKI) announces that a dividend of $0.1012 per share will be paid on June 15, 2020 to shareholders of record on May 25, 2020. The dividend will be an ‘eligible dividend’ for Canadian income tax purposes. The ex-dividend date is May 22, 2020.Enhanced Dividend Reinvestment PlanParkland’s enhanced Dividend Reinvestment Plan (“Enhanced DRIP”) allows shareholders to reinvest their cash dividends to purchase additional Parkland shares from treasury at a 5% per share discount to the average of the daily volume weighted average trading prices during the Pricing Period. For further details on the Enhanced DRIP and the Pricing Period, please visit http://www.parkland.ca/en/investors/dividend/.Shareholders who wish to...

Continue reading

Investar Holding Corporation Changes its 2020 Annual Meeting of Shareholders to a Virtual Format

BATON ROUGE, La., May 13, 2020 (GLOBE NEWSWIRE) — Investar Holding Corporation (the “Company”), the holding company for Investar Bank, National Association, announced today that, due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic and recommendations from government authorities, the location of the Company’s 2020 Annual Meeting of Shareholders (including any adjournments or postponements thereof, the “Annual Meeting”) has been changed to a virtual only format.As previously announced, the Annual Meeting will be held at 3:00 p.m. Central Time on Wednesday, May 27, 2020. Shareholders will not be able to attend the Annual Meeting in person.As described in the proxy materials for the Annual Meeting that were previously made available to shareholders, you are entitled to participate in the...

Continue reading

Lexicon Pharmaceuticals Announces Preclinical Efficacy Data on Telotristat Ethyl’s Antiproliferative Effects Against Various Cancer Cell Lines

THE WOODLANDS, Texas, May 13, 2020 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today additional data on XERMELO’s® (telotristat ethyl) antiproliferative effects against cultured liposarcoma, colon cancer and cholangiocarcinoma cell lines that were published online in conjunction with the American Society of Clinical Oncology (ASCO) 2020 annual meeting (May 29 – June 2, 2020). XERMELO is approved for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy, but is not currently approved for any other use.Tumor growth inhibition when exposed to telotristat ethyl was most pronounced in the liposarcoma cell line, followed by the colon cancer and cholangiocarcinoma cell lines. “We are pleased that this preclinical...

Continue reading

Stifel Announces Pricing of $400 Million of Senior Notes

ST. LOUIS, May 13, 2020 (GLOBE NEWSWIRE) — Stifel Financial Corp. (NYSE: SF) today announced the pricing of $400 million principal amount of 4.000% Senior Notes due 2030 (the “Notes”).  The Notes will bear interest at a rate of 4.000% per annum and will mature on May 15, 2030.  The net proceeds from this offering will be used for general corporate purposes.  The offering is expected to close on May 20, 2020, subject to customary closing conditions.The Notes will be issued pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission on Form S-3 and available for review on the Securities and Exchange Commission’s website at www.sec.gov. Keefe, Bruyette & Woods, A Stifel Company, BofA Securities, Inc., Citigroup Global Markets Inc., Morgan Stanley & Co. LLC and Wells Fargo...

Continue reading

Black Hills Corp. Announces Upcoming Investor Meetings and Reaffirms Guidance

RAPID CITY, S.D., May 13, 2020 (GLOBE NEWSWIRE) — Black Hills Corp. (NYSE: BKH) today announced that members of its senior management team will visit with investors May 14 during the Credit Suisse 2020 Utilities, Power & Clean Tech Virtual Conference and May 18 and 19 during the virtually hosted American Gas Association Financial Forum.Management reaffirms its guidance range most recently issued on May 5, and will be available to discuss guidance, its response to the COVID-19 pandemic and related impacts on the company’s business.The materials produced for these meetings will be available on the Black Hills Corp. website at www.blackhillscorp.com under the “Investor Relations” section prior to the meetings.Black Hills CorporationBlack Hills Corp. (NYSE: BKH) is a customer-focused, growth-oriented utility company with a tradition...

Continue reading

Corvus Pharmaceuticals to Present Data on Refinement of the Adenosine Gene Signature and Ciforadenant in Renal Cell Cancer at the ASCO20 Virtual Scientific Program

BURLINGAME, Calif., May 13, 2020 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient selection, today announced that updated data reporting refinements of the Adenosine Gene Signature  as a predictive biomarker for patients treated with ciforadenant, the Company’s adenosine A2A receptor antagonist, will be presented in an electronic poster presentation at the American Society of Clinical Oncology’s (ASCO) upcoming ASCO20 Virtual Scientific Program, to be held May 29-31, 2020.The data is based on results from  the Company’s Phase 1b/2 clinical trial of ciforadenant in patients with advanced refractory renal cell cancer (RCC) and...

Continue reading

The Keg Royalties Income Fund Reports First Quarter 2020 Financial Results

Not for distribution to U.S. News wire services or dissemination in the U.S.VANCOUVER, British Columbia, May 13, 2020 (GLOBE NEWSWIRE) — The Keg Royalties Income Fund (the “Fund”) (TSX: KEG.UN) and Keg Restaurants Ltd (“KRL”) are pleased to announce the financial results of the Fund for the first quarter of 2020.HIGHLIGHTSAll 106 Keg restaurants in the Royalty Pool closed as at March 17, 2020 due to the COVID-19 pandemicKRL system sales down 14.3% to $144.1M for the 13-week periodKRL same store sales down 0.3% for the comparable 8-week periodsRoyalty Pool sales down 13.9% to $142.7M for the quarterDistributable cash up 7.4% to 36.6 cents/Fund unit for the quarterPayout ratio was 77.6% for the first quarter of 2020The Royalty Pool sales reported by the 106 Keg restaurants in the Royalty Pool were $142,653,000 for the quarter, a decrease...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.